赛升药业
(300485)
| 流通市值：23.69亿 | | | 总市值：41.66亿 |
| 流通股本：2.74亿 | | | 总股本：4.82亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 180,725,174.26 | 90,438,931.64 | 404,718,439.82 | 308,627,146.45 |
| 营业总成本 | 185,441,288.45 | 81,693,249.46 | 416,569,516.64 | 302,545,729.03 |
| 其他经营收益 | | | | |
| 营业利润 | -172,339,196.48 | 3,699,095.87 | 12,416,070.71 | 59,248,798.67 |
| 利润总额 | -171,619,375.12 | 4,442,352.14 | 12,303,605.48 | 59,195,382.11 |
| 净利润 | -145,910,631.44 | 3,815,266.3 | 7,789,641.78 | 48,551,017.63 |
| 每股收益 | | | | |
| 其他综合收益 | -797,357.78 | -400,326.58 | -707,988.21 | -431,253.9 |
| 综合收益总额 | -146,707,989.22 | 3,414,939.72 | 7,081,653.57 | 48,119,763.73 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 1,595,053,981.32 | 1,751,176,609.38 | 1,687,530,433.28 | 1,780,433,815.57 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,767,379,986.39 | 1,814,562,810.03 | 1,880,872,315.33 | 1,824,313,373.23 |
| 资产总计 | 3,362,433,967.71 | 3,565,739,419.41 | 3,568,402,748.61 | 3,604,747,188.8 |
| 流动负债: | | | | |
| 流动负债合计 | 75,144,606.5 | 87,169,567.3 | 92,297,347.75 | 81,684,924.47 |
| 非流动负债: | | | | |
| 非流动负债合计 | 55,988,843.97 | 82,705,703.36 | 83,656,191.83 | 89,574,945.14 |
| 负债合计 | 131,133,450.47 | 169,875,270.66 | 175,953,539.58 | 171,259,869.61 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 3,212,063,925.3 | 3,375,237,916.78 | 3,370,974,955.2 | 3,408,540,257.12 |
| 股东权益合计 | 3,231,300,517.24 | 3,395,864,148.75 | 3,392,449,209.03 | 3,433,487,319.19 |
| 负债和股东权益合计 | 3,362,433,967.71 | 3,565,739,419.41 | 3,568,402,748.61 | 3,604,747,188.8 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 221,961,156.58 | 111,887,747.87 | 486,765,974.22 | 354,021,432.08 |
| 经营活动现金流出小计 | 210,556,852.34 | 100,936,037.02 | 459,687,238.4 | 323,579,478.12 |
| 经营活动产生的现金流量净额 | 11,404,304.24 | 10,951,710.85 | 27,078,735.82 | 30,441,953.96 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 754,316,802.5 | 405,917,247.64 | 1,140,309,591.97 | 1,954,168,185.43 |
| 投资活动现金流出小计 | 737,071,207.17 | 369,898,866.06 | 1,186,035,103.16 | 1,990,237,705.35 |
| 投资活动产生的现金流量净额 | 17,245,595.33 | 36,018,381.58 | -45,725,511.19 | -36,069,519.92 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 14,475,649.32 | - | 19,987,800 | 19,987,800 |
| 筹资活动现金流出小计 | 34,729,598.59 | 245,443.17 | 250,888.94 | - |
| 筹资活动产生的现金流量净额 | -20,253,949.27 | -245,443.17 | 19,736,911.06 | 19,987,800 |
| 汇率变动对现金及现金等价物的影响 | -797,357.78 | -400,326.58 | -528,891.61 | -298,613.9 |
| 现金及现金等价物净增加额 | 7,598,592.52 | 46,324,322.68 | 561,244.08 | 14,061,620.14 |
| 期末现金及现金等价物余额 | 83,422,526.91 | 122,148,257.07 | 75,823,934.39 | 89,324,310.45 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 7,598,592.52 | - | 561,244.08 | - |